| 臺大學術典藏 |
2021-10-27T03:22:22Z |
Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients �V A Taiwanese study
|
Wu T.-H.; Lee L.J.-H.; CHANG-TSU YUAN; Chen T.W.-W.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-10-04T07:15:39Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T05:41:27Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Chen L.-Y.; Molina-Vila M.A.; Ruan S.-Y.; Su K.-Y.; Liao W.-Y.; KAI-LUN YU; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.H.; Rosell R.; Yang P.-C. |
| 臺大學術典藏 |
2021-09-17T03:21:17Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
SHENG-KAI LIANG; Ko J.-C.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-09T05:25:29Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-09T05:25:27Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients
|
ZONG-HAN YAO; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-01T01:53:45Z |
Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas
|
Wu P.-F.; Huang W.-C.; Yang J.C.-H.; Lu Y.-S.; Shih J.-Y.; Wu S.-G.; Lin C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:43Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; ANN-LII CHENG; Lai M.-S. |
| 臺大學術典藏 |
2021-09-01T01:53:41Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S.; Lin C.-C.; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; Yang J.C.-H.; ANN-LII CHENG; Ghalib M.H.; Chuadhary I.; Goel S. |
| 臺大學術典藏 |
2021-08-31T06:42:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:20Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
Liao B.-C.; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; ANN-LII CHENG; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:49Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; ANN-LII CHENG; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:47Z |
The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases
|
Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Lin Z.-Z.; Lan K.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:45Z |
Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice
|
Liang Y.-H.; Shao Y.-Y.; Liao B.-C.; Lee H.-S.; Yang J.C.-H.; Chen H.-M.; Chiang C.-J.; ANN-LII CHENG; Lai M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T.; Yang J.C.-H.; Shitara K.; Naito Y.; ANN-LII CHENG; Sarashina A.; Pronk L.C.; Takeuchi Y.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; ANN-LII CHENG; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-23T02:42:25Z |
Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit
|
Hsiue E.H.-C.; Lee P.-L.; YUNG-HSUAN CHEN; Wu T.-H.; Cheng C.-F.; Cheng K.-M.; Yang P.-C.; Chen H.-W.; Lin P.-Y.; Chiang D.-L.; Wu H.-D.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-08-20T08:00:44Z |
Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study
|
BIN-CHI LIAO; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
|
BIN-CHI LIAO; Lin C.C.; Shih J.Y.; Yang J.C.H. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma
|
BIN-CHI LIAO; Shao Y.-Y.; Chen H.-M.; Shau W.-Y.; Lin Z.-Z.; Kuo R.N.; Lai C.-L.; Chen K.-H.; Cheng A.-L.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-20T08:00:43Z |
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
|
BIN-CHI LIAO; Lin C.-C.; Yang J.C.-H. |
